BCRX
Price:
$7.98
Market Cap:
$1.65B
BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX9930, an oral factor D inhibitor, which is in Phase II clinical trial for complement-mediated diseases; BCX9250, an oral activin receptor-like kinase-2 inhibitor that is in Phase I clinical trial to treat fibrodysplasia ossificans progressiva; and Galidesivir, a RNA dependent-RNA polymerase inhibitor, w...[Read more]
Industry
Biotechnology
IPO Date
1994-03-04
Stock Exchange
NASDAQ
Ticker
BCRX
According to BioCryst Pharmaceuticals, Inc.’s latest financial reports and current stock price. The company's current Enterprise Value is 2.42B. This represents a change of 36.90% compared to the average of 1.77B of the last 4 quarters.
The mean historical Enterprise Value of BioCryst Pharmaceuticals, Inc. over the last ten years is 1.18B. The current 2.42B Enterprise Value has changed 20.38% with respect to the historical average. Over the past ten years (40 quarters), BCRX's Enterprise Value was at its highest in in the March 2022 quarter at 3.22B. The Enterprise Value was at its lowest in in the March 2016 quarter at 225.81M.
Average
1.18B
Median
827.61M
Minimum
369.30M
Maximum
2.57B
Discovering the peaks and valleys of BioCryst Pharmaceuticals, Inc. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 197.52%
Maximum Annual Enterprise Value = 2.57B
Minimum Annual Increase = -57.44%
Minimum Annual Enterprise Value = 369.30M
Year | Enterprise Value | Change |
---|---|---|
2023 | 1.89B | -26.58% |
2022 | 2.57B | 0.05% |
2021 | 2.57B | 133.87% |
2020 | 1.10B | 197.52% |
2019 | 369.30M | -57.44% |
2018 | 867.79M | 107.06% |
2017 | 419.09M | -15.87% |
2016 | 498.13M | -34.09% |
2015 | 755.81M | -4.01% |
2014 | 787.42M | 83.77% |
The current Enterprise Value of BioCryst Pharmaceuticals, Inc. (BCRX) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
2.34B
5-year avg
1.70B
10-year avg
1.18B
BioCryst Pharmaceuticals, Inc.’s Enterprise Value is less than TG Therapeutics, Inc. (3.44B), less than Axsome Therapeutics, Inc. (4.35B), greater than Intercept Pharmaceuticals, Inc. (915.81M), greater than Seres Therapeutics, Inc. (286.75M), less than Madrigal Pharmaceuticals, Inc. (4.91B), greater than Kezar Life Sciences, Inc. (30.16M), greater than Immunic, Inc. (41.96M), greater than Atara Biotherapeutics, Inc. (104.92M), greater than Pieris Pharmaceuticals, Inc. (2.77M), less than Apellis Pharmaceuticals, Inc. (5.11B), less than Blueprint Medicines Corporation (6.16B), less than Karuna Therapeutics, Inc. (12.43B), less than Mirati Therapeutics, Inc. (3.91B), greater than Day One Biopharmaceuticals, Inc. (1.01B), greater than Anavex Life Sciences Corp. (297.94M), greater than Cassava Sciences, Inc. (1.08B), greater than INmune Bio, Inc. (90.68M), greater than BioVie Inc. (-6703650.00), greater than Cognition Therapeutics, Inc. (-5041239.00), less than Viking Therapeutics, Inc. (5.95B), greater than X4 Pharmaceuticals, Inc. (40.79M), greater than PDS Biotechnology Corporation (74.53M),
Company | Enterprise Value | Market cap |
---|---|---|
3.44B | $3.41B | |
4.35B | $4.47B | |
915.81M | $794.69M | |
286.75M | $145.36M | |
4.91B | $5.30B | |
30.16M | $40.82M | |
41.96M | $120.71M | |
104.92M | $46.55M | |
2.77M | $22.50M | |
5.11B | $5.00B | |
6.16B | $5.47B | |
12.43B | $12.60B | |
3.91B | $4.12B | |
1.01B | $1.25B | |
297.94M | $436.70M | |
1.08B | $1.29B | |
90.68M | $116.32M | |
-6703650.00 | $15.23M | |
-5041239.00 | $22.87M | |
5.95B | $6.00B | |
40.79M | $109.78M | |
74.53M | $107.88M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like BioCryst Pharmaceuticals, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like BioCryst Pharmaceuticals, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the Enterprise Value?
How can you use the Enterprise Value?
What is BioCryst Pharmaceuticals, Inc.'s Enterprise Value?
What is the highest Enterprise Value for BioCryst Pharmaceuticals, Inc. (BCRX)?
What is the 3-year average Enterprise Value for BioCryst Pharmaceuticals, Inc. (BCRX)?
What is the 5-year average Enterprise Value for BioCryst Pharmaceuticals, Inc. (BCRX)?
How does the current Enterprise Value for BioCryst Pharmaceuticals, Inc. (BCRX) compare to its historical average?